Enhancing the Safety of Warfarin in Nursing Homes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00682773|
Recruitment Status : Completed
First Posted : May 22, 2008
Last Update Posted : August 4, 2011
|Condition or disease||Intervention/treatment||Phase|
|Adverse Drug Events (ADEs)||Other: SBAR||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||26 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Primary Purpose:||Health Services Research|
|Official Title:||Enhancing the Safety of Warfarin in Nursing Homes|
|Study Start Date :||September 2006|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||September 2009|
No Intervention: 1
Usual care, no educational intervention.
Usual care, nursing home nursing staff receive educational intervention on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
- The proportion of time that nursing home residents receiving warfarin have their international normalized ratios (INRs) within the target therapeutic range [ Time Frame: one year ]
- The time to next INR measurement after an out-of-range INR. [ Time Frame: one year ]
- Rates of adverse events (bleeds and thromboembolic events) [ Time Frame: one year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00682773
|United States, Connecticut|
|Middletown, Connecticut, United States, 06457|
|United States, Massachusetts|
|Meyers Primary Care Institute|
|Worcester, Massachusetts, United States, 01605|
|Principal Investigator:||Jerry H Gurwitz, MD||Meyers Primary Care Institute/University of Massachusetts Medical School|